Kiniksa Pharmaceuticals Ltd. (KNSA)’s Financial Results Comparing With Verona Pharma plc (NASDAQ:VRNA)

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) and Verona Pharma plc (NASDAQ:VRNA) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kiniksa Pharmaceuticals Ltd. N/A 0.00 103.23M -1.92 0.00
Verona Pharma plc N/A 0.00 N/A -2.34 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Kiniksa Pharmaceuticals Ltd. and Verona Pharma plc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Kiniksa Pharmaceuticals Ltd. and Verona Pharma plc.

Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals Ltd. 0.00% 0% 0%
Verona Pharma plc 0.00% 0% 0%

Analyst Recommendations

The next table highlights the given recommendations and ratings for Kiniksa Pharmaceuticals Ltd. and Verona Pharma plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kiniksa Pharmaceuticals Ltd. 0 0 1 3.00
Verona Pharma plc 0 0 0 0.00

The upside potential is 48.57% for Kiniksa Pharmaceuticals Ltd. with consensus price target of $26.

Insider & Institutional Ownership

Roughly 74.8% of Kiniksa Pharmaceuticals Ltd. shares are owned by institutional investors while 65.7% of Verona Pharma plc are owned by institutional investors. Insiders owned roughly 12.97% of Kiniksa Pharmaceuticals Ltd.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kiniksa Pharmaceuticals Ltd. 1.59% 2.4% -12.37% -16.65% 0% -36.21%
Verona Pharma plc 0.35% -0.1% -47.23% -56.64% -54.61% -39.79%

For the past year Kiniksa Pharmaceuticals Ltd.’s stock price has smaller decline than Verona Pharma plc.

Summary

Kiniksa Pharmaceuticals Ltd. beats on 4 of the 5 factors Verona Pharma plc.

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companyÂ’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.